M
Mohit Butaney
Researcher at Mayo Clinic
Publications - 83
Citations - 6808
Mohit Butaney is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 23, co-authored 52 publications receiving 5775 citations. Previous affiliations of Mohit Butaney include University of Minnesota & Harvard University.
Papers
More filters
Journal ArticleDOI
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
Esra A. Akbay,Esra A. Akbay,Shohei Koyama,Julian Carretero,Abigail Altabef,Abigail Altabef,Jeremy H. Tchaicha,Jeremy H. Tchaicha,Camilla L. Christensen,Camilla L. Christensen,Oliver Mikse,Oliver Mikse,Andrew D. Cherniack,Ellen M. Beauchamp,Trevor J. Pugh,Matthew D. Wilkerson,Peter E. Fecci,Mohit Butaney,Jacob B. Reibel,Jacob B. Reibel,Margaret Soucheray,Travis J. Cohoon,Travis J. Cohoon,Pasi A. Jänne,Matthew Meyerson,Matthew Meyerson,D. Neil Hayes,Geoffrey I. Shapiro,Takeshi Shimamura,Lynette M. Sholl,Scott J. Rodig,Gordon J. Freeman,Peter S. Hammerman,Glenn Dranoff,Kwok-Kin Wong +34 more
TL;DR: It is shown that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines.
Journal ArticleDOI
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T. Shaw,Beow Y. Yeap,Benjamin Solomon,Gregory J. Riely,Justin F. Gainor,Jeffrey A. Engelman,Geoffrey I. Shapiro,Daniel B. Costa,Sai-Hong Ignatius Ou,Mohit Butaney,Ravi Salgia,Robert G. Maki,Marileila Varella-Garcia,Robert C. Doebele,Yung-Jue Bang,Kimary Kulig,Paulina Selaru,Yiyun Tang,Keith D. Wilner,Eunice L. Kwak,Jeffrey W. Clark,A. John Iafrate,D. Ross Camidge +22 more
TL;DR: In patients with advanced, ALK-positive NSCLC, crizotinib therapy is associated with improved survival compared with that of crizotib-naive controls, and ALK rearrangement is not a favourable prognostic factor in advanced NSClC.
Journal ArticleDOI
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R. Oxnard,Cloud P. Paweletz,Yanan Kuang,Stacy L. Mach,Allison O'Connell,Melissa M. Messineo,Jason J. Luke,Mohit Butaney,Paul Kirschmeier,David M. Jackman,Pasi A. Jänne +10 more
TL;DR: Serial quantification of plasma genotype allows noninvasive assessment of response and resistance, including detection of resistance mutations up to 16 weeks before radiographic progression, and demonstrates assay qualities that could allow effective translation into a clinical diagnostic.
Journal ArticleDOI
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki,Jussi Koivunen,Atsuko Ogino,Masahiko Yanagita,Sarah Nikiforow,Wei Zheng,Christopher S. Lathan,J. Paul Marcoux,Jinyan Du,Katsuhiro Okuda,Marzia Capelletti,Takeshi Shimamura,Dalia Ercan,Magda Stumpfova,Yun Xiao,Stanislawa Weremowicz,Mohit Butaney,Stephanie Heon,Keith D. Wilner,James G. Christensen,Michael J. Eck,Kwok-Kin Wong,Neal I. Lindeman,Nathanael S. Gray,Scott J. Rodig,Pasi A. Jänne +25 more
TL;DR: Two mechanisms of ALK TKI resistance identified from a crizotinib-treated non-small cell lung cancer (NSCLC) patient and in a cell line generated from the resistant tumor (DFCI076) as well as from studying a resistant version of the ALk TKI (TAE684)-sensitive H3122 cell line.
Journal ArticleDOI
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
Aria Vaishnavi,Marzia Capelletti,Anh T. Le,Severine Kako,Mohit Butaney,Dalia Ercan,Sakshi Mahale,Kurtis D. Davies,Dara L. Aisner,Dara L. Aisner,Amanda B. Pilling,Eamon M. Berge,Jhingook Kim,Hidefumi Sasaki,Seung-Il Park,Gregory V. Kryukov,Levi A. Garraway,Levi A. Garraway,Peter S. Hammerman,Julia Haas,Steven W. Andrews,Doron Lipson,Philip J. Stephens,V.A. Miller,Marileila Varella-Garcia,Marileila Varella-Garcia,Pasi A. Jänne,Robert C. Doebele,Robert C. Doebele +28 more
TL;DR: Tumor samples from 3 of 91 patients with lung cancer without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.